<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Glaucoma Drainage Devices - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjWH-31@OHwG4j-uNdmwAAABk","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Glaucoma_Drainage_Devices","wgTitle":"Glaucoma Drainage Devices","wgCurRevisionId":89560,"wgRevisionId":89560,"wgArticleId":852,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Glaucoma_Drainage_Devices","wgRelevantArticleId":852,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":
"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,
"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.page.gallery.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init",
"ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.page.gallery.styles%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Glaucoma drainage devices are designed to divert aqueous humor from the anterior chamber to an external reservoir, where a fibrous capsule forms about 4-6 weeks after surgery and regulates flow. These devices have shown success in controlling intraocular pressure (IOP) in eyes with previously failed&amp;#160;trabeculectomy&amp;#160;and in eyes with insufficient conjunctiva because of scarring from prior surgical procedures or injuries. They also have demonstrated success in complicated glaucomas, such as uveitic glaucoma, neovascular glaucoma, and pediatric and developmental glaucomas, among others."/>
<meta name="date" content="2023-02-09"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Glaucoma Drainage Devices" href="/w/index.php?title=Special:ExportRDF/Glaucoma_Drainage_Devices&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Glaucoma_Drainage_Devices rootpage-Glaucoma_Drainage_Devices layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Glaucoma+Drainage+Devices" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Glaucoma+Drainage+Devices" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyw1f2f"></button>
					<div class="collapse navbar-collapse hbpzyw1f2f" id="hbpzyw1f2f">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Glaucoma_Drainage_Devices" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Glaucoma_Drainage_Devices&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Glaucoma_Drainage_Devices&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Glaucoma_Drainage_Devices&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Glaucoma_Drainage_Devices&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Glaucoma_Drainage_Devices#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Glaucoma Drainage Devices</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Sarwat.Salim.SEC" title="User:Sarwat.Salim.SEC">Sarwat Salim MD, FACS</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Sarwat.Salim.SEC" title="User:Sarwat.Salim.SEC">Sarwat Salim MD, FACS</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a>,&#160;<a href="/User:Koushik.Tripathy" title="User:Koushik.Tripathy">Koushik Tripathy, MD (AIIMS), FRCS (Glasgow)</a>,&#160;<a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a> on February 10, 2023.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Glaucoma_Drainage_Devices&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Glaucoma_Drainage_Devices&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Preoperative_Considerations"><span class="tocnumber">2</span> <span class="toctext">Preoperative Considerations</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Surgical_Technique"><span class="tocnumber">3</span> <span class="toctext">Surgical Technique</span></a>
<ul>
<li class="toclevel-2 tocsection-4"><a href="#Modifications_To_Prevent_Hypotony_with_Nonvalved_Implants"><span class="tocnumber">3.1</span> <span class="toctext">Modifications To Prevent Hypotony with Nonvalved Implants</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Pars_Plana_Insertion"><span class="tocnumber">3.2</span> <span class="toctext">Pars Plana Insertion&#160;</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Site_of_Implantation"><span class="tocnumber">3.3</span> <span class="toctext">Site of Implantation&#160;</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Role_of_Antifibrosis_Agents"><span class="tocnumber">3.4</span> <span class="toctext">Role of Antifibrosis Agents&#160;</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-8"><a href="#Postoperative_Course"><span class="tocnumber">4</span> <span class="toctext">Postoperative Course</span></a>
<ul>
<li class="toclevel-2 tocsection-9"><a href="#Complications_and_Management"><span class="tocnumber">4.1</span> <span class="toctext">Complications and Management&#160;</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Clinical_Outcomes"><span class="tocnumber">5</span> <span class="toctext">Clinical Outcomes</span></a>
<ul>
<li class="toclevel-2 tocsection-11"><a href="#Comparative_Studies_of_Various_Glaucoma_Drainage_Devices"><span class="tocnumber">5.1</span> <span class="toctext">Comparative Studies of Various Glaucoma Drainage Devices</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#Surgical_Outcomes_in_Refractory_or_Difficult_Glaucomas"><span class="tocnumber">5.2</span> <span class="toctext">Surgical Outcomes in Refractory or Difficult Glaucomas</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Comparative_Studies_of_Glaucoma_Drainage_Devices_and_Trabeculectomy"><span class="tocnumber">5.3</span> <span class="toctext">Comparative Studies of Glaucoma Drainage Devices and Trabeculectomy</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-14"><a href="#Conclusion"><span class="tocnumber">6</span> <span class="toctext">Conclusion</span></a></li>
<li class="toclevel-1 tocsection-15"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>Glaucoma drainage devices are designed to divert aqueous humor from the anterior chamber to an external reservoir, where a fibrous capsule forms about 4-6 weeks after surgery and regulates flow. These devices have shown success in controlling intraocular pressure (IOP) in eyes with previously failed&#160;trabeculectomy&#160;and in eyes with insufficient conjunctiva because of scarring from prior surgical procedures or injuries. They also have demonstrated success in complicated glaucomas, such as uveitic glaucoma, neovascular glaucoma, and pediatric and developmental glaucomas, among others. 
</p><p>Since the introduction of the first glaucoma drainage device, <i>Molteno implant</i>, various modifications of the original design and improvements in surgical techniques over the past 40 years have led to greater success and lower complication rates. In addition, other glaucoma drainage devices have been introduced and offer unique features designed to facilitate implantation, improve IOP control, and reduce acute postoperative hypotony. 
</p><p>Currently, the glaucoma drainage devices are available in different sizes, materials, and design with the presence or absence of an IOP regulating valve. The nonvalved devices include the Molteno (IOP, Inc., Costa Mesa, CA, USA, and Molteno Ophthalmic Limited, Dunedin, New Zealand), Baerveldt (Advanced Medical Optics, Inc., Santa Ana, CA, USA), Shocket, and Eagle Vision implants (Eagle Vision, Inc. Memphis, TN, USA). Unlike the nonvalved devices, the valved or flow-restrictive devices allow only unidirectional flow from the anterior chamber to the subconjunctival space with a minimum opening pressure. The most commonly used valved implant is the Ahmed glaucoma valve, AGV (New World Medical, Rancho Cucamonga, CA, USA). <a href="/Glaucoma_Drainage_Devices#Table1" title="Glaucoma Drainage Devices">Table 1</a> provides a summary of commercially available devices with their respective characteristics. 
</p><p>This review article will discuss the currently available glaucoma drainage devices, preoperative considerations and surgical technique, description and management of various complications, surgical outcomes in refractory glaucomas, comparative studies of various glaucoma drainage devices, and comparative studies of glaucoma drainage devices and trabeculectomy. 
</p><p><br />
</p>
<h1><span class="mw-headline" id="Preoperative_Considerations">Preoperative Considerations</span></h1>
<p><b>Patient Selection<br /></b>Glaucoma drainage devices have traditionally been reserved for patients with severe uncontrolled glaucoma who have failed previous glaucoma surgery. In addition, the devices appear to be advantageous as a primary procedure in patients with a high likelihood of trabeculectomy failure, including neovascular and uveitic glaucomas <sup id="cite_ref-brown1_1-0" class="reference"><a href="#cite_note-brown1-1">&#91;1&#93;</a></sup> <sup id="cite_ref-mermoud2_2-0" class="reference"><a href="#cite_note-mermoud2-2">&#91;2&#93;</a></sup> <sup id="cite_ref-:3_3-0" class="reference"><a href="#cite_note-:3-3">&#91;3&#93;</a></sup> <sup id="cite_ref-sidoti4_4-0" class="reference"><a href="#cite_note-sidoti4-4">&#91;4&#93;</a></sup> <sup id="cite_ref-:5_5-0" class="reference"><a href="#cite_note-:5-5">&#91;5&#93;</a></sup> <sup id="cite_ref-:6_6-0" class="reference"><a href="#cite_note-:6-6">&#91;6&#93;</a></sup><sup id="cite_ref-:7_7-0" class="reference"><a href="#cite_note-:7-7">&#91;7&#93;</a></sup>. They are commonly used in the management of congenital and developmental glaucomas. <sup id="cite_ref-:8_8-0" class="reference"><a href="#cite_note-:8-8">&#91;8&#93;</a></sup> <sup id="cite_ref-:9_9-0" class="reference"><a href="#cite_note-:9-9">&#91;9&#93;</a></sup> <sup id="cite_ref-:10_10-0" class="reference"><a href="#cite_note-:10-10">&#91;10&#93;</a></sup> <sup id="cite_ref-damata11_11-0" class="reference"><a href="#cite_note-damata11-11">&#91;11&#93;</a></sup> <sup id="cite_ref-ceballos12_12-0" class="reference"><a href="#cite_note-ceballos12-12">&#91;12&#93;</a></sup> <sup id="cite_ref-papadaki13_13-0" class="reference"><a href="#cite_note-papadaki13-13">&#91;13&#93;</a></sup> <sup id="cite_ref-billson14_14-0" class="reference"><a href="#cite_note-billson14-14">&#91;14&#93;</a></sup> Additional indications include traumatic glaucoma, aphakic and pseudophakic glaucoma, post-keratoplasty glaucoma, and other secondary glaucomas .<sup id="cite_ref-munoz15_15-0" class="reference"><a href="#cite_note-munoz15-15">&#91;15&#93;</a></sup> <sup id="cite_ref-netland16_16-0" class="reference"><a href="#cite_note-netland16-16">&#91;16&#93;</a></sup> <sup id="cite_ref-coleman17_17-0" class="reference"><a href="#cite_note-coleman17-17">&#91;17&#93;</a></sup> <sup id="cite_ref-netland18_18-0" class="reference"><a href="#cite_note-netland18-18">&#91;18&#93;</a></sup> Recently, interest has increased in using these devices as a primary surgical procedure for uncontrolled primary open-angle glaucoma. 
</p><p><b>Clinical Examination<br /></b>Careful preoperative examination and planning are essential for successful surgical outcomes. Clinicians should assess mobility of the conjunctiva to determine the best quadrant for drainage implant insertion. The iris should be inspected under high magnification to detect neovascularization to consider preoperative use of anti-vascular endothelial growth factor (VEGF) agents to minimize intraoperative and postoperative bleeding. Anterior chamber depth should be assessed to determine if tube insertion in the anterior chamber would be safe without touching the iris or cornea. Gonioscopy should be performed preoperatively to determine the locations of peripheral anterior synechiae which may interfere with the tube insertion into the anterior chamber intraoperatively. The lenticular status of the eye should be noted. The tube may be placed in the sulcus in a pseudophakic eye or pars plana in an aphakic, vitrectomized eye. In an eye with a cataract, a combined surgery may be considered. 
</p><p><b>Selection of Glaucoma Drainage Device<br /></b>For a beginning surgeon, valved devices may be preferred as the surgical technique is simpler with localization to one quadrant without manipulation of the adjacent rectus muscles. IOP control in the early postoperative period is more predictable with these devices because of flow-restricting mechanisms. In patients with poor compliance with postoperative medication use and follow-up visits, valved implants may be preferred because they usually require less postoperative follow-up and care. 
</p><p>The amount of conjunctival scarring may determine the size of the implant and available area for a single-plate versus double-plate device. The most important factor determining the type of implant selected is the target IOP, both in the short-run and long-run. Early IOP control is determined by the presence or absence of a valve in an implant, as the tube offers no resistance to aqueous flow. The valved devices provide more immediate IOP control and a lower rate of hypotony. Because nonvalved devices are often occluded with a stent or ligature suture, the postoperative IOP is unchanged and requires continuation of all preoperative medications until the fibrous capsule forms. With all devices, long-term IOP control depends on the <i>surface area of the implant</i>, which determines bleb size, tissue response to the implant, and thickness of the fibrous capsule controlling percolation of aqueous humor through the bleb wall. 
</p><p>Plate material has been studied in various studies to determine its influence on final IOP, as it may affect tissue reaction and the degree of bleb encapsulation. Ayyala et al. <sup id="cite_ref-:19_19-0" class="reference"><a href="#cite_note-:19-19">&#91;19&#93;</a></sup> <sup id="cite_ref-:20_20-0" class="reference"><a href="#cite_note-:20-20">&#91;20&#93;</a></sup> demonstrated more inflammation with the polypropylene plate (Molteno implant) than with the silicone plate (Krupin implant) when inserted subconjunctivally in rabbits. Two retrospective studies compared AGV silicone (model FP7) and polypropylene (model S2) and reported similar results with both models in terms of IOP control, final visual acuity, and postoperative antiglaucoma medications .<sup id="cite_ref-mackenzie21_21-0" class="reference"><a href="#cite_note-mackenzie21-21">&#91;21&#93;</a></sup> <sup id="cite_ref-:22_22-0" class="reference"><a href="#cite_note-:22-22">&#91;22&#93;</a></sup> In one of these studies, the silicone valve was associated with fewer serious complications  <sup id="cite_ref-mackenzie21_21-1" class="reference"><a href="#cite_note-mackenzie21-21">&#91;21&#93;</a></sup>. The AGV silicone and polypropylene material has also been investigated in a prospective, multicenter, comparative series, which reported improved final IOP control with the silicone model compared with the polypropylene model <sup id="cite_ref-:23_23-0" class="reference"><a href="#cite_note-:23-23">&#91;23&#93;</a></sup>. The investigators observed more Tenon’s cysts in the polypropylene group. 
</p><p>Plate size of various implants has been investigated to determine its influence on the final IOP. Heuer et al.  <sup id="cite_ref-heuer24_24-0" class="reference"><a href="#cite_note-heuer24-24">&#91;24&#93;</a></sup> reported improved IOP control with the Molteno double-plate when compared with the single-plate in a prospective study assessing outcomes in aphakic and pseudophakic glaucoma. In a retrospective study, the double-plate Molteno demonstrated lower mean IOP when compared with the single-plate AGV, 13.3 ± 5.1 mm Hg vs. 19 ± 5.8 mm Hg (P=0.009), respectively, at 24 months .<sup id="cite_ref-ayyala25_25-0" class="reference"><a href="#cite_note-ayyala25-25">&#91;25&#93;</a></sup> In a prospective study comparing 350-mm<sup>2</sup> and 500-mm<sup>2</sup> Baerveldt implants, Lloyd et al. <sup id="cite_ref-lloyd26_26-0" class="reference"><a href="#cite_note-lloyd26-26">&#91;26&#93;</a></sup> reported statistically comparable results with respect to IOP control, visual acuity, and complications. In another prospective study comparing 350-mm<sup>2</sup> and 500-mm<sup>2</sup> Baerveldt implants, Britt et al. <sup id="cite_ref-:27_27-0" class="reference"><a href="#cite_note-:27-27">&#91;27&#93;</a></sup> found better IOP control with the 350-mm<sup>2</sup> Baerveldt implant than with the 500-mm<sup>2</sup> model. These studies indicate that size of the implant does matter, but to a limited extent. Further studies are warranted to determine which one of these variables- size, shape, or composition is most likely to affect long-term success of glaucoma drainage devices. 
</p><p><b>Anesthetic Considerations<br /></b>The choice of anesthesia for inserting a glaucoma drainage device depends on the presence of other medical co-morbidities, the cooperation level of the patient, and the comfort of the surgeon. The most commonly used anesthesia is a peribulbar or retrobulbar block which provides both akinesia and anesthesia. A sub-Tenon injection is also a good alternative. Topical or intracameral anesthesia is usually not sufficient because of manipulation of extraocular muscles with some implants. General anesthesia may be reserved for patients with special circumstances, such as claustrophobia or altered mental status 
</p><p><br />
</p>
<ul class="gallery mw-gallery-traditional">
		<li class="gallerybox" style="width: 515px"><div style="width: 515px">
			<div class="thumb" style="width: 510px;"><div style="margin:15px auto;"><a href="/File:Eagle-Vision_Implant.jpg" class="image"><img alt="Eagle-Vision Implant.jpg" src="/w/images/1/c/cb/Eagle-Vision_Implant.jpg" decoding="async" width="337" height="240" /></a></div></div>
			<div class="gallerytext">
			</div>
		</div></li>
		<li class="gallerybox" style="width: 515px"><div style="width: 515px">
			<div class="thumb" style="width: 510px;"><div style="margin:15px auto;"><a href="/File:Single_Plate_Molteno.jpg" class="image"><img alt="Single Plate Molteno.jpg" src="/w/images/1/f/f0/Single_Plate_Molteno.jpg" decoding="async" width="322" height="240" /></a></div></div>
			<div class="gallerytext">
			</div>
		</div></li>
		<li class="gallerybox" style="width: 515px"><div style="width: 515px">
			<div class="thumb" style="width: 510px;"><div style="margin:15px auto;"><a href="/File:Baerveldt_Implants.jpg" class="image"><img alt="Baerveldt Implants.jpg" src="/w/images/1/thumb/5/58/Baerveldt_Implants.jpg/443px-Baerveldt_Implants.jpg" decoding="async" width="443" height="240" srcset="/w/images/1/5/58/Baerveldt_Implants.jpg 1.5x" /></a></div></div>
			<div class="gallerytext">
			</div>
		</div></li>
		<li class="gallerybox" style="width: 515px"><div style="width: 515px">
			<div class="thumb" style="width: 510px;"><div style="margin:15px auto;"><a href="/File:Ahmed-Glaucoma_Valve.jpg" class="image"><img alt="Ahmed-Glaucoma Valve.jpg" src="/w/images/1/b/ba/Ahmed-Glaucoma_Valve.jpg" decoding="async" width="240" height="240" /></a></div></div>
			<div class="gallerytext">
			</div>
		</div></li>
</ul>
<p><b>Pictures&#160;courtesy of: IOP, Inc., Costa Mesa, CA, USA, New World Medical, Rancho Cucamonga, CA, USA,Advanced Medical Optics, Inc., Santa Ana, CA, USA, and Eagle Vision, Inc. Memphis, TN, USA</b>
</p><p><span id="Table1"></span>
</p>
<table class="wikitable">
<caption><b>Table 1 Commercially Available Glaucoma Drainage Devices</b>
</caption>
<tbody><tr>
<th colspan="4">A. Valved Implants
</th></tr>
<tr>
<th>Type
</th>
<th>Model
</th>
<th>Size
</th>
<th>Material
</th></tr>
<tr>
<td colspan="4">Ahmed Implant
</td></tr>
<tr>
<td>Single Plate</td>
<td>S2</td>
<td>184 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Pediatric Size</td>
<td>S3</td>
<td>96 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Double Plate</td>
<td>B1</td>
<td>364 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Single Plate</td>
<td>FP7</td>
<td>184 mm<sup>2</sup></td>
<td>Silicone
</td></tr>
<tr>
<td>Pediatric Size</td>
<td>FP8</td>
<td>96 mm<sup>2</sup></td>
<td>Silicone
</td></tr>
<tr>
<td>Double Plate</td>
<td>FX1</td>
<td>364 mm<sup>2</sup></td>
<td>Silicone
</td></tr>
<tr>
<td>Pars Plana</td>
<td>PS2</td>
<td>184 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Pars Plana (Ped)</td>
<td>PS3</td>
<td>96 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Pars Plana</td>
<td>PC7</td>
<td>184 mm<sup>2</sup></td>
<td>Silicone
</td></tr>
<tr>
<td>Pars Plana (Ped)</td>
<td>PC8</td>
<td>96 mm<sup>2</sup></td>
<td>Silicone
</td></tr>
<tr>
<th colspan="4">B. Nonvalved Implants
</th></tr>
<tr>
<th>Type
</th>
<th>Model
</th>
<th>Size
</th>
<th>Material
</th></tr>
<tr>
<td colspan="4">Baerveldt Implant
</td></tr>
<tr>
<td>Single Plate</td>
<td>103-250</td>
<td>250 mm<sup>2</sup></td>
<td>Silicone
</td></tr>
<tr>
<td>Single Plate</td>
<td>101-350</td>
<td>350 mm<sup>2</sup></td>
<td>Silicone
</td></tr>
<tr>
<td>Pars Plana</td>
<td>102-350</td>
<td>350 mm<sup>2</sup></td>
<td>Silicone
</td></tr>

<tr>
<td colspan="4">Clearpath Implant
</td></tr>
<tr>
<td>Single Plate
</td>
<td>250
</td>
<td>250mm<sup>2</sup>
</td>
<td>Silicone
</td></tr>
<tr>
<td>Single Plate
</td>
<td>350
</td>
<td>350mm<sup>2</sup>
</td>
<td>Silicone
</td></tr>
<tr>
<td>Eagle Vision Implant</td>
<td>EG365</td>
<td>365 mm<sup>2</sup></td>
<td>Silicone
</td></tr>

<tr>
<td colspan="4">Molteno Implant
</td></tr>
<tr>
<td>Single Plate</td>
<td>S1</td>
<td>137 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Single Plate/Ridge</td>
<td>D1</td>
<td>137 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>For microphthalmic eyes</td>
<td>M1</td>
<td>50 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Double Plate</td>
<td>R2/L2</td>
<td>274 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Double Plate/Ridge</td>
<td>DR2/DL2</td>
<td>274 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Molteno 3/Single Plate</td>
<td>GS</td>
<td>175 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
<tr>
<td>Molteno 3/Double Plate</td>
<td>GL</td>
<td>230 mm<sup>2</sup></td>
<td>Polypropylene
</td></tr>
</tbody></table>
<h1><span class="mw-headline" id="Surgical_Technique">Surgical Technique</span></h1>
<p>Implantation of a glaucoma drainage device requires careful attention to detail at every step of the procedure to improve results and minimize postoperative complications. Initially, a fornix-based or limbus-based conjunctival incision is created to allow adequate exposure for insertion of the plate. A corneal or scleral suture can be placed to improve exposure in the working quadrant. The implant is anchored between two rectus muscles with the anterior edge approximately <i>8 to 10 m</i>m posterior to the limbus. Larger implants (Baerveldt) are inserted with the long axis directed toward the apex of the orbit and then rotated hori¬zontally so that the tube points directly toward the anterior chamber and the wings of the implant are under the rectus muscles. If a two plate implant is used, one plate is positioned in each of two quadrants. The tube connecting the two plates may be passed under or over the intervening rectus muscle. With all valved implants, prior to the plate anchorage, the tube should be primed with balanced salt solution with a 30-gauge cannula to ensure that the valve leaflets are not fused after sterilization techniques. The tube of the nonvalved implant should be irrigated as well to ensure its patency. 
</p><p><iframe width="560" height="315" src="//www.youtube-nocookie.com/embed/8a85f7_8VrM" frameborder="0" allowfullscreen=""></iframe>
</p><p>Once the implant has been appropriately positioned, the plate is secured to the globe with two non-absorbable sutures (8-0 or 9-0 nylon sutures on a spatulated needle). The suture knots should be rotated into the fixation eyelets to prevent erosion through the conjunctiva. Secure attachment to the underlying sclera is essential to prevent anterior, posterior, or lateral migration of the implant during the postoperative period 
</p><p>After the plate is attached to the globe, the tube is laid across the cornea and cut with a sharp scissors to create a beveled edge with the opening toward the cornea. The tube should extend approximately <i>2.5 to 3 mm</i> into the anterior chamber to minimize the risk of tube-cornea touch or retraction out of the anterior chamber. A 23-gauge needle is used to create a track through which the tube is inserted into the anterior chamber just anterior and parallel to the iris. The tube may be secured to the sclera a few millimeters anterior to the plate with 7- 0 or 8-0 Vicryl suture. This suture helps to stabilize the tube and should not be tight; otherwise, it will restrict flow in valved devices. 
</p><p>The tube is often covered to prevent its erosion through the conjunctiva. Patch graft materials include processed pericardium, sclera, fascia lata, dura, or cornea. The patch graft should be secured to the globe with interrupted sutures at the anterior corners by using either 8-0 Vicryl or nylon sutures. In lieu of a patch graft, a partial thickness scleral flap can be constructed. The needle track and tube entry are done under this flap. The flap is then sutured with 10-0 nylon sutures. More recently, tunneled incisions have been utilized as an alternative to both grafts and flaps.  After the patch graft has been placed, the conjunctiva and Tenon layers are pulled over the plate, tube, and patch graft and secured into place with 8-0 Vicryl suture. In some cases, the monofilament 9-0 Vicryl suture is preferred because of its higher tensile strength and finer vascular needle to prevent buttonholes when handling thin conjunctiva. 
</p><p>At the end of the operation, the eye should be inspected to ensure that the implant plate, patch graft, and intraocular portion of the tube are in good position. Fluorescein drops or strips can be used to inspect the conjunctiva for leaks. Any buttonholes found in the conjunctiva should be closed with 9-0 Vicryl suture. At the conclusion of the procedure, a subconjunctival injection of antibiotic and steroid is given. 
</p>
<h2><span class="mw-headline" id="Modifications_To_Prevent_Hypotony_with_Nonvalved_Implants">Modifications To Prevent Hypotony with Nonvalved Implants</span></h2>
<p><b>Internal Tube Occlusion (Stent)</b> Aqueous drainage through a nonvalved device can be regulated in the early postoperative period by passing a 4-0 or 5-0 Prolene or nylon suture through the lumen of the implant. Once the fibrous capsule around the plate has formed, the stent suture is removed at the slit lamp under local anesthesia. 
</p><p><b>External Tube Occlusion (Ligature)<br /></b>The flow of aqueous humor through a nonvalved device can also be restricted by placing a suture ligature around the external aspect of the tube. The external occlusion may be accomplished using a non-absorbable 7-0 suture with a releasable knot or a 7-0 or 8-0 absorbable Vicryl suture tied around the tube. Alternatively, 9-0 nylon or 10-0 Prolene suture may be used to ligate the tube inside the anterior chamber to allow for later suture lysis with the argon laser. Some surgeons create venting&#160; slits anterior to the ligature suture with either a needle or a knife for aqueous drainage, thereby allowing immediate IOP control in the early postoperative period.  
</p><p><b>Two Stage Procedure<br /></b>To prevent postoperative hypotony, a shunt procedure may be performed in two stages. In the first stage, the plate is attached to the globe and the tube is left in the subconjunctival space without entering the eye. Four to 6 weeks later, after a capsule has formed around the implant, the conjunctiva is opened and the tube is inserted into the anterior chamber to complete the procedure. 
</p>
<h2><span class="mw-headline" id="Pars_Plana_Insertion">Pars Plana Insertion&#160;</span></h2>
<p>The tube of the glaucoma drainage device is most commonly placed in the anterior chamber. However, the tube may also be placed in the sulcus in a pseudophakic eye or in the pars plana in a vitrectomized eye. This procedure can be accomplished using one of two options: a Pars Plana Clip (Model PC, New World Medical, Inc., Rancho Cucamonga, CA, USA), which can be used with any drainage device or <i>Hoffman elbow</i>, which is mounted on a Baerveldt 350-mm<sup>2</sup> implant (Advanced Medical Optics, Inc., Santa Ana, CA, USA).&#160; 
</p>
<h2><span class="mw-headline" id="Site_of_Implantation">Site of Implantation&#160;</span></h2>
<p>With the exception of the two-plate implants, most glaucoma implants are placed in a single quadrant. Whenever possible, single-plate implants should be placed in the supero-temporal quadrant. This area provides the easiest access for the surgeon to implant the plate and is least likely to produce motility disturbances. Implantation of a large plate aqueous shunt in the supero-nasal quadrant has been associated with Brown's superior oblique tendon syndrome <sup id="cite_ref-ball28_28-0" class="reference"><a href="#cite_note-ball28-28">&#91;28&#93;</a></sup>. Substantial hypertropias and limitations of down gaze have been reported with inferior implantation of two-plate Molteno and the Krupin valve with disc <sup id="cite_ref-christman29_29-0" class="reference"><a href="#cite_note-christman29-29">&#91;29&#93;</a></sup>. In eyes containing silicone oil, the implant is placed in the inferior quadrant to minimize loss of oil, which is lighter than aqueous and floats up.&#160; 
</p>
<h2><span class="mw-headline" id="Role_of_Antifibrosis_Agents">Role of Antifibrosis Agents&#160;</span></h2>
<p>Using anti-metabolites with improved success in trabeculectomy led to considerable interest in using these agents with glaucoma drainage devices. One early study indicated that patients receiving mitomycin C at the time of glaucoma implant surgery had lower final IOP, required fewer post-operative medications, and had less pronounced hypertensive phases; however, the duration of the post-operative hypotensive phase was prolonged and was associated with an increase in choroidal effusions, flat anterior chambers, and other post-operative complications <sup id="cite_ref-:30_30-0" class="reference"><a href="#cite_note-:30-30">&#91;30&#93;</a></sup>. However, subsequent studies have not shown these agents to be effective. Two retrospective studies reported no benefit of intraoperative use of mitomycin C with Baerveldt implants <sup id="cite_ref-:31_31-0" class="reference"><a href="#cite_note-:31-31">&#91;31&#93;</a></sup><sup id="cite_ref-:32_32-0" class="reference"><a href="#cite_note-:32-32">&#91;32&#93;</a></sup>. Two prospective randomized trials studied the effectiveness of intraoperative use of mitomycin C with Molteno and AGV implantation. Neither trial demonstrated higher success rates with intraoperative mitomycin C in terms of final IOP, visual acuity, and number of antiglaucoma medications required postoperatively <sup id="cite_ref-:33_33-0" class="reference"><a href="#cite_note-:33-33">&#91;33&#93;</a></sup> <sup id="cite_ref-:34_34-0" class="reference"><a href="#cite_note-:34-34">&#91;34&#93;</a></sup>. As a result of these investigations, antifibrosis agents are not currently used with glaucoma drainage devices. 
</p>
<h1><span class="mw-headline" id="Postoperative_Course">Postoperative Course</span></h1>
<p>Following glaucoma drainage implant surgery, the patient is seen on postoperative day 1, and attention is paid to the tube position and wound architecture. A topical antibiotic and steroid are started four times daily and continued for 4 to 6 weeks. Initial follow-up is at 1 week, and the frequency of visits depends on the clinical status of the eye. For valved implants, preoperative glaucoma medications are discontinued to prevent hypotony. For nonvalved implants, the glaucoma medications are usually continued until a fibrous capsule forms around the plate, at which point the ligature suture may spontaneously open. If further IOP lowering is required, the stent can also be removed. 
</p>
<h2><span class="mw-headline" id="Complications_and_Management">Complications and Management&#160;</span></h2>
<p>Glaucoma drainage devices can be associated with various postoperative complications. The early postoperative complications are similar to other filtration procedures including flat chambers, hypotony, and suprachoroidal hemorrhage <sup id="cite_ref-brown1_1-1" class="reference"><a href="#cite_note-brown1-1">&#91;1&#93;</a></sup><sup id="cite_ref-heuer24_24-1" class="reference"><a href="#cite_note-heuer24-24">&#91;24&#93;</a></sup><sup id="cite_ref-lloyd26_26-1" class="reference"><a href="#cite_note-lloyd26-26">&#91;26&#93;</a></sup><sup id="cite_ref-molteno35_35-0" class="reference"><a href="#cite_note-molteno35-35">&#91;35&#93;</a></sup>. 
</p><p><b>Hypotony<br /></b>Hypotony and its related sequelae, choroidal effusions or suprachoroidal hemorrhage, are more commonly observed with the nonvalved drainage devices. Early postoperative hypotony usually results from wound leak, inflammation, incomplete occlusion of the tube, or larger venting slits with nonvalved implants. Valved implants usually reduce, but do not eliminate hypotony. Hypotonous eyes are conservatively managed as long as the anterior chamber depth is maintained. If there is lenticular-corneal touch, then a viscoelastic should be injected to reform the anterior chamber. Associated choroidal effusions are generally treated with corticosteroid and cycloplegic agents. If these measures fail, surgical revision may be required. 
</p><p><b>Valve Malfunction <br /></b>This is a rare complication. All valved devices should be primed at the time of the surgery as sterilization techniques may lead to adhesion of the valve membranes that prevents flow to the plate <sup id="cite_ref-:36_36-0" class="reference"><a href="#cite_note-:36-36">&#91;36&#93;</a></sup>. In addition, careful surgical handling during insertion is required to prevent damage to the plastic rivets holding the valve <sup id="cite_ref-:37_37-0" class="reference"><a href="#cite_note-:37-37">&#91;37&#93;</a></sup>. 
</p><p><b>Hyphema <br /></b>Hyphema may occur following procedures performed on eyes with neovascular glaucoma. It is seen less commonly now with the preoperative use of anti-VEGF agents. 
</p><p><b>Scleral Perforation<br /></b>Scleral perforation is a rare complication during anchorage of the plate to the sclera. Care must be taken in buphthalmic eyes and eyes with collagen vascular diseases. 
</p><p><b>Tube-Related Problems<br /></b>Care should be taken to place the tube in the anterior chamber correctly. If the tube is placed too anteriorly, it will cause decompensation of the corneal endothelium. If the tube is placed too posteriorly, it will cause inflammation by rubbing on the iris and may also result in cataract formation if it touches the anterior lens capsule. 
</p><p>If the tube is inadvertently cut too short, either an angiocatheter or tube extender can be used to obtain the desired length <sup id="cite_ref-:38_38-0" class="reference"><a href="#cite_note-:38-38">&#91;38&#93;</a></sup>. 
</p><p>Tube block from blood, vitreous, fibrin, or iris incarceration in the early postoperative period can occur. A Nd:YAG laser may be helpful in some cases 
<sup id="cite_ref-:39_39-0" class="reference"><a href="#cite_note-:39-39">&#91;39&#93;</a></sup>, whereas in others, a return trip to the operating room to clear the tube end may be required, especially in eyes with retained vitreous that may necessitate vitrectomy. If the tube is clogged by a blood clot, tissue plasminogen activator (0.1-0.2 ml of 5-20 µg) may be beneficial to dissolve the clot. Tube obstruction because of kinking of the tube has been reported after pars plana AGV insertion <sup id="cite_ref-:40_40-0" class="reference"><a href="#cite_note-:40-40">&#91;40&#93;</a></sup>. The obstruction was treated with a pars plana clip. 
</p><p>Tube retraction and anterior migration are more commonly seen in children. As the eye grows, the tube may retract or touch the corneal endothelium. Retracted tubes can be lengthened with tube extenders or, alternatively, can be placed in the pars plana. Anterior migration of the tube can be fixed by shortening its length and a more posterior reinsertion. 
</p><p><b>Tube Erosion and Endophthalmitis<br /></b>Tube erosion usually results from conjunctival melting near the limbus overlying the tube and may be related to poor patch graft preparation or placement; however, even without these factors, melting of the conjunctiva and patch graft occur over time and result in tube exposure. Replacing the patch graft and mobilizing a conjunctival graft may be useful in repairing these defects. An exposed tube or plate is considered an ocular emergency requiring prompt surgical intervention to prevent endophthalmitis. The risk of endophthalmitis has been reported to be more common in children <sup id="cite_ref-:41_41-0" class="reference"><a href="#cite_note-:41-41">&#91;41&#93;</a></sup>. 
</p><p><b>Migration or Expulsion of the Plate <br /></b>These are seen less commonly than are tube migration and tube erosion. Migration and expulsion usually result from placing the plate too anteriorly. 
</p><p><b>Corneal Decompensation<br /></b>Poor tube placement with lens-cornea touch or persistent flat chamber from hypotony may result in corneal edema. In eyes that have undergone penetrating keratoplasty, the risk of graft failure in eyes that develop a flat chamber postoperatively is high <sup id="cite_ref-beebe42_42-0" class="reference"><a href="#cite_note-beebe42-42">&#91;42&#93;</a></sup><sup id="cite_ref-:43_43-0" class="reference"><a href="#cite_note-:43-43">&#91;43&#93;</a></sup><sup id="cite_ref-:44_44-0" class="reference"><a href="#cite_note-:44-44">&#91;44&#93;</a></sup><sup id="cite_ref-:45_45-0" class="reference"><a href="#cite_note-:45-45">&#91;45&#93;</a></sup>. The use of valved and stented implants that better maintain the anterior chamber depth reduces this complication. Alternatively, placing the tube in pars plana helps to avoid corneal or graft decompensation. 
</p><p><b>Overhanging Bleb<br /></b>If the patch graft is too thick or the plate is too anterior, an overhanging bleb may be created resulting in chronic Dellen formation and ocular irritation. This complication is best prevented by appropriate plate and patch graft placement during surgery. 
</p><p><b>Strabismus<br /></b>Extraocular muscle imbalance with devastating diplopia may also occur and is particularly common in cases of inferior implant placement. This imbalance usually results from a mass effect of the plate and the surrounding bleb on adjacent extraocular muscles. Other possible causes include Faden or posterior fixation suture effect induced by scarring under the rectus muscles, entrapment of superior oblique muscle or fat fibrosis syndrome because of inadvertent manipulation of orbital fat <sup id="cite_ref-christman29_29-1" class="reference"><a href="#cite_note-christman29-29">&#91;29&#93;</a></sup><sup id="cite_ref-:46_46-0" class="reference"><a href="#cite_note-:46-46">&#91;46&#93;</a></sup>, or a pseudo-Brown’s syndrome from supero-nasal insertion of drainage devices <sup id="cite_ref-ball28_28-1" class="reference"><a href="#cite_note-ball28-28">&#91;28&#93;</a></sup><sup id="cite_ref-:47_47-0" class="reference"><a href="#cite_note-:47-47">&#91;47&#93;</a></sup>. Diplopia secondary to drainage devices is difficult to treat and various treatment options include prisms, muscle surgery, or even removal of the drainage implant. 
</p><p><b>Hypertensive Phase<br /></b>Hypertensive phase is characterized by elevated IOP, typically in 30- to 50- mm Hg range, occurring anywhere between 1 and 6 weeks postoperatively. This condition has been reported after inserting all types of drainage devices, but more common with valved implants <sup id="cite_ref-ayyala25_25-1" class="reference"><a href="#cite_note-ayyala25-25">&#91;25&#93;</a></sup><sup id="cite_ref-:48_48-0" class="reference"><a href="#cite_note-:48-48">&#91;48&#93;</a></sup>. In eyes with hypertensive phase, the tube does not appear to be occluded by any of the methods described above, and elevated IOP is presumably secondary to a thick-walled bleb over the plate of the implant, which decrease permeability of the aqueous humor through the conjunctiva. Treatment options for hypertensive phase include medical therapy, digital massage, bleb needling with or without 5-fluorouracil, and possible surgical excision of the bleb <sup id="cite_ref-:49_49-0" class="reference"><a href="#cite_note-:49-49">&#91;49&#93;</a></sup><sup id="cite_ref-:50_50-0" class="reference"><a href="#cite_note-:50-50">&#91;50&#93;</a></sup>. When all these measures fail, a second drainage implant or cyclodestructive procedure may be considered.<br />
</p>
<h1><span class="mw-headline" id="Clinical_Outcomes">Clinical Outcomes</span></h1>
<p>Glaucoma drainage devices have been shown to provide effective IOP control in eyes that have failed prior surgery or have a poor prognosis for standard filtration surgery <sup id="cite_ref-mermoud2_2-1" class="reference"><a href="#cite_note-mermoud2-2">&#91;2&#93;</a></sup><sup id="cite_ref-munoz15_15-1" class="reference"><a href="#cite_note-munoz15-15">&#91;15&#93;</a></sup><sup id="cite_ref-heuer24_24-2" class="reference"><a href="#cite_note-heuer24-24">&#91;24&#93;</a></sup><sup id="cite_ref-lloyd26_26-2" class="reference"><a href="#cite_note-lloyd26-26">&#91;26&#93;</a></sup><sup id="cite_ref-beebe42_42-1" class="reference"><a href="#cite_note-beebe42-42">&#91;42&#93;</a></sup><sup id="cite_ref-:51_51-0" class="reference"><a href="#cite_note-:51-51">&#91;51&#93;</a></sup>. At 2 years of follow-up, most studies indicated overall success rates of 50% to 80% with the outcome depending on the type of glaucoma present and type of implant selected. 
</p>
<h2><span class="mw-headline" id="Comparative_Studies_of_Various_Glaucoma_Drainage_Devices">Comparative Studies of Various Glaucoma Drainage Devices</span></h2>
<p>A few retrospective studies have compared clinical outcomes of AGV versus Baerveldt implants <sup id="cite_ref-:52_52-0" class="reference"><a href="#cite_note-:52-52">&#91;52&#93;</a></sup><sup id="cite_ref-wang53_53-0" class="reference"><a href="#cite_note-wang53-53">&#91;53&#93;</a></sup><sup id="cite_ref-tsai54_54-0" class="reference"><a href="#cite_note-tsai54-54">&#91;54&#93;</a></sup>. Of these, the larger series <sup id="cite_ref-tsai54_54-1" class="reference"><a href="#cite_note-tsai54-54">&#91;54&#93;</a></sup> consisted of 118 eyes with a follow-up of 48 months, at which time the final success in terms of IOP control was reported to be comparable in both groups: 62% for the Ahmed group and 64% for the Baerveldt group (P=0.84). The postoperative complications differed in the two groups, with hypotony-related issues in the Baerveldt group and hypertensive crisis in the Ahmed group requiring antiglaucoma medications <sup id="cite_ref-tsai54_54-2" class="reference"><a href="#cite_note-tsai54-54">&#91;54&#93;</a></sup>. These studies had limitations given their retrospective designs in that the study groups were not similar: the eyes undergoing Ahmed valve implantation had higher preoperative IOP in one study <sup id="cite_ref-tsai54_54-3" class="reference"><a href="#cite_note-tsai54-54">&#91;54&#93;</a></sup>, and the mean age at implantation was significantly different in another study, although this study found a higher success rate with Baerveldt than with Ahmed: 83% versus 67%, respectively, at 42 months <sup id="cite_ref-wang53_53-1" class="reference"><a href="#cite_note-wang53-53">&#91;53&#93;</a></sup>. 
</p><p>Double-plate Molteno was compared to AGV in a retrospective, case control study with 30 subjects in each arm <sup id="cite_ref-molteno35_35-1" class="reference"><a href="#cite_note-molteno35-35">&#91;35&#93;</a></sup>. At 24 months follow-up, mean IOP was 13.3 ± 5.1 mm Hg in the Molteno group and 19.0 ± 5.8 mm Hg in the AGV group (P=0.009). This study also reported a high incidence of postoperative hypotony in the nonvalved group and hypertensive crisis in the valved group. 
</p><p>The Ahmed Baerveldt Comparison Study (ABC) is a multicenter, randomized, prospective clinical trial that recently completed recruitment. The preliminary results of this trial were presented at the annual meeting of American Glaucoma Society in Naples, FL, March 4-5, 2010 <sup id="cite_ref-:55_55-0" class="reference"><a href="#cite_note-:55-55">&#91;55&#93;</a></sup><sup id="cite_ref-:56_56-0" class="reference"><a href="#cite_note-:56-56">&#91;56&#93;</a></sup>. Two hundred and seventy-six subjects with uncontrolled glaucoma received either an AGV (model FP7) or a Baerveldt implant (model 350 mm<sup>2</sup>). The majority of the recruited subjects had either primary open-angle glaucoma or neovascular glaucoma. Forty-two percent of the subjects had previously failed trabeculectomy. The mean baseline IOP was 30 mm Hg. Failure was defined as an IOP greater than 21 mm Hg and less than 6 mm Hg, less than 20% IOP reduction from baseline, repeat surgery, or loss of light perception. At 1 year, the mean IOP was 15.4± 5.5 mm Hg in the Ahmed group and 13.2± 6.8 mm Hg in the Baerveldt group (P=.007). The cumulative probability of failure was 16.4% and 12.3% in the AGV and Baerveldt groups, respectively. The Baerveldt group required more surgical interventions postoperatively.   
</p><p>Five Year pooled data from both the AGV and ABC found significantly lower failure rates, rate of de novo glaucoma surgery and number of medications in the Baervedlt group, although with a higher risk of hypotony.<sup id="cite_ref-57" class="reference"><a href="#cite_note-57">&#91;57&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Surgical_Outcomes_in_Refractory_or_Difficult_Glaucomas">Surgical Outcomes in Refractory or Difficult Glaucomas</span></h2>
<p>Using different models in controlling IOP in eyes with neovascular glaucoma, Sidoti et al. <sup id="cite_ref-sidoti4_4-1" class="reference"><a href="#cite_note-sidoti4-4">&#91;4&#93;</a></sup> assessed the effectiveness of the Baerveldt implant. The life-table success rates were 79% and 56% at 12 and 18 months, respectively. Although there were no significant differences noted between various models in terms of percentage of postoperative IOP reduction or complication rates, the postoperative visual loss was reported to be common in these eyes as a result of underlying disease. In another study, IOP control was reported to be adequate to keep the eyes comfortable, but the visual outcome of patients with neovascular glaucoma was determined primarily by underlying disease process with diabetic patients doing significantly better than did patients with a central retinal vein occlusion <sup id="cite_ref-mermoud2_2-2" class="reference"><a href="#cite_note-mermoud2-2">&#91;2&#93;</a></sup>. 
</p><p>Both AGV and Baerveldt implants have been shown to be effective in controlling IOP in uveitic eyes <sup id="cite_ref-damata11_11-1" class="reference"><a href="#cite_note-damata11-11">&#91;11&#93;</a></sup><sup id="cite_ref-ceballos12_12-1" class="reference"><a href="#cite_note-ceballos12-12">&#91;12&#93;</a></sup><sup id="cite_ref-papadaki13_13-1" class="reference"><a href="#cite_note-papadaki13-13">&#91;13&#93;</a></sup>. In a retrospective, noncomparative case series, Da Mata et al. <sup id="cite_ref-damata11_11-2" class="reference"><a href="#cite_note-damata11-11">&#91;11&#93;</a></sup> reported a cumulative probability of success of 94% at 1 year after AGV implant. In this series, all patients had uveitis controlled prior to surgery with immunomodulatory therapy, which may have contributed to the high success rate. Using different models of Baerveldt implant, Ceballos et al. <sup id="cite_ref-ceballos12_12-2" class="reference"><a href="#cite_note-ceballos12-12">&#91;12&#93;</a></sup> reported a similar cumulative life-table success rate of 91.7% at 24 months. The AGV implant was found to be moderately successful when long-term results were reported for eyes with uveitic glaucoma <sup id="cite_ref-papadaki13_13-2" class="reference"><a href="#cite_note-papadaki13-13">&#91;13&#93;</a></sup>. The qualified success rates were 57% and 39% at 1 and 4 years, respectively. At 4 years, 74% of the patients required adjunctive glaucoma therapy to control IOP. 
</p><p>The Ahmed glaucoma valve was shown to be very effective in treating medically uncontrolled IOP after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. IOP was reduced from a mean of 44± 11.8 mm Hg before surgery to 14± 4.2 mm Hg at the most recent follow-up after surgery (P&lt;0.001). The number of glaucoma medications reduced after surgery was also statistically significant <sup id="cite_ref-:57_58-0" class="reference"><a href="#cite_note-:57-58">&#91;58&#93;</a></sup>. 
</p><p>Coleman et al. <sup id="cite_ref-:58_59-0" class="reference"><a href="#cite_note-:58-59">&#91;59&#93;</a></sup> reported clinical outcomes of AGV in eyes with prior or concurrent penetrating keratoplasty. The cumulative probabilities of success at 12 and 20 months were 75.4% ± 8.2% and 51.5% ± 11.4%, respectively. Ayyala et al. <sup id="cite_ref-:59_60-0" class="reference"><a href="#cite_note-:59-60">&#91;60&#93;</a></sup> compared trabeculectomy with mitomycin C, glaucoma drainage device implantation with both valved and nonvalved implants, and Nd:YAG cyclophotocoagulation laser to manage intractable glaucoma after penetrating keratoplasty. No differences were found among the three glaucoma procedures in terms of final IOP control and graft failure. The laser-treated group tended to have higher incidence of graft failure, glaucoma failure, and loss of vision, but these results were not statistically significant. Glaucoma drainage devices have also been reported to be effective in glaucoma associated with keratoprosthesis <sup id="cite_ref-netland18_18-1" class="reference"><a href="#cite_note-netland18-18">&#91;18&#93;</a></sup>. 
</p><p>Glaucoma drainage devices are increasingly being used in pediatric glaucoma which is often refractory to conventional medical and surgical therapy <sup id="cite_ref-billson14_14-1" class="reference"><a href="#cite_note-billson14-14">&#91;14&#93;</a></sup><sup id="cite_ref-munoz15_15-2" class="reference"><a href="#cite_note-munoz15-15">&#91;15&#93;</a></sup><sup id="cite_ref-netland16_16-1" class="reference"><a href="#cite_note-netland16-16">&#91;16&#93;</a></sup><sup id="cite_ref-coleman17_17-1" class="reference"><a href="#cite_note-coleman17-17">&#91;17&#93;</a></sup><sup id="cite_ref-englert60_61-0" class="reference"><a href="#cite_note-englert60-61">&#91;61&#93;</a></sup><sup id="cite_ref-budenz61_62-0" class="reference"><a href="#cite_note-budenz61-62">&#91;62&#93;</a></sup><sup id="cite_ref-:62_63-0" class="reference"><a href="#cite_note-:62-63">&#91;63&#93;</a></sup>. Billson et al. <sup id="cite_ref-billson14_14-2" class="reference"><a href="#cite_note-billson14-14">&#91;14&#93;</a></sup> reported favorable outcomes in developmental glaucomas using two-stage implantation of the Molteno implant where final IOP with adjunctive glaucoma medications was less than 21 mm Hg in 78% of the cases. Coleman et al. <sup id="cite_ref-coleman17_17-2" class="reference"><a href="#cite_note-coleman17-17">&#91;17&#93;</a></sup> evaluated AGV in pediatric glaucoma cases and reported cumulative probabilities of success at 12 and 24 months to be 77.9% ± 8.8% and 60.6% ± 13.7%, respectively. Englert et al. <sup id="cite_ref-englert60_61-1" class="reference"><a href="#cite_note-englert60-61">&#91;61&#93;</a></sup> reported AGV to be effective in refractory pediatric glaucoma cases, even in eyes with previous cycloablative procedures. Budenz et al. <sup id="cite_ref-budenz61_62-1" class="reference"><a href="#cite_note-budenz61-62">&#91;62&#93;</a></sup> evaluated the Baerveldt implant in childhood glaucoma associated with Sturge-Weber syndrome. They concluded that two-stage Baerveldt surgery was both effective and safe in these children. At average follow-up of 35 months, all 10 eyes had IOP less than 21 mm Hg on medications without the need for additional glaucoma surgery.
</p>
<h2><span class="mw-headline" id="Comparative_Studies_of_Glaucoma_Drainage_Devices_and_Trabeculectomy">Comparative Studies of Glaucoma Drainage Devices and Trabeculectomy</span></h2>
<p>Wilson et al. <sup id="cite_ref-:63_64-0" class="reference"><a href="#cite_note-:63-64">&#91;64&#93;</a></sup> compared short and intermediate results of trabeculectomy and AGV in a randomized clinical trial and reported statistically lower mean IOP with trabeculectomy than with AGV at weeks 6-15 and months 11-13. The cumulative probability of success was 83.6% for the trabeculectomy group and 88.1% for the AGV (P=0.43). There was no significant difference in complication rates between the two groups, but the AGV group required more glaucoma medications postoperatively. The same investigators subsequently reported the long-term results of these two procedures <sup id="cite_ref-:64_65-0" class="reference"><a href="#cite_note-:64-65">&#91;65&#93;</a></sup>. The cumulative probabilities of success at months 41-52 were 68.1% for the trabeculectomy group and 69.8% for the AGV group (P= 0.86). Adjunctive medication requirement was also comparable in both groups with longer follow-up. 
</p><p>Gedde et al. <sup id="cite_ref-:65_66-0" class="reference"><a href="#cite_note-:65-66">&#91;66&#93;</a></sup><sup id="cite_ref-:66_67-0" class="reference"><a href="#cite_note-:66-67">&#91;67&#93;</a></sup> have been investigating the clinical outcomes of nonvalved tube shunt, specifically the Baerveldt 350 mm<sup>2</sup>, and standard trabeculectomy with mitomycin C in a multicenter, randomized clinical trial. A total of 212 eyes were enrolled with IOP ≥ 18 mm Hg and ≤ 40 mm Hg. The main outcome measures were IOP, visual acuity, and reoperation for glaucoma. At 1 year follow-up, IOP control was good in both groups, with slightly lower pressures in the Baerveldt group. The mean IOP was 12.7± 3.9 mm Hg in the trabeculectomy group and 12.4± 3.9 mm Hg in the Baerveldt group (P=0.73). The cumulative probability of failure during the first year was 3.9% in the Baerveldt group and 13.5% in the trabeculectomy group (P=0.17). Intraoperative complications occurred in 7% of the Baerveldt group and 10% of the trabeculectomy group (P=.59). Postoperative complications were more common in the trabeculectomy group than in the Baerveldt group, 57% versus 34%, respectively. Adjunctive glaucoma medications were required more in the Baerveldt group. Longer follow-up of this study will elucidate further details on IOP control and other variables with these two commonly performed glaucoma surgeries.<br />
</p>
<h1><span class="mw-headline" id="Conclusion">Conclusion</span></h1>
<p>Glaucoma drainage devices have been successful in controlling IOP in eyes with previously failed trabeculectomy and difficult glaucomas. Since their introduction over 40 years ago, numerous modifications in design and improvements in surgical technique have enhanced clinical outcomes and minimized complications. These devices are available in different sizes, materials, and design. The decision to choose a particular type of drainage device depends on a patient’s underlying characteristics in terms of preoperative IOP and optic nerve status, desired long-term IOP control, and the surgeon’s comfort and preference. Careful preoperative screening and planning along with meticulous surgical technique help minimize postoperative complications. 
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-brown1-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-brown1_1-0">1.0</a></sup> <sup><a href="#cite_ref-brown1_1-1">1.1</a></sup></span> <span class="reference-text">Brown RD, Cairns JE. Experience with the Molteno long tube implant. Trans Ophthalmol Soc UK 1983;103:297-312.</span>
</li>
<li id="cite_note-mermoud2-2"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-mermoud2_2-0">2.0</a></sup> <sup><a href="#cite_ref-mermoud2_2-1">2.1</a></sup> <sup><a href="#cite_ref-mermoud2_2-2">2.2</a></sup></span> <span class="reference-text">Mermoud A, Salmon JF, Alexander P, et al. Molteno tube implantation for neovascular glaucoma: long term results and factors influencing out¬come. Ophthalmology 1993;100:897-902.</span>
</li>
<li id="cite_note-:3-3"><span class="mw-cite-backlink"><a href="#cite_ref-:3_3-0">↑</a></span> <span class="reference-text">Hill RA, Nguyen QH, Baerveldt G, et al. Trabeculectomy and Molteno implantation for glaucomas associated with uveitis. Ophthalmology 1993;100:903-908.</span>
</li>
<li id="cite_note-sidoti4-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-sidoti4_4-0">4.0</a></sup> <sup><a href="#cite_ref-sidoti4_4-1">4.1</a></sup></span> <span class="reference-text">Sidoti PA, Dunphy TR, Baerveldt G, et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology 1995;102:1107-1118.</span>
</li>
<li id="cite_note-:5-5"><span class="mw-cite-backlink"><a href="#cite_ref-:5_5-0">↑</a></span> <span class="reference-text">Da Mata A, Burk SE, Netland PA, et al. Management of uveitic glaucoma with Ahmed glaucoma valve implantation. Opthalmology 1999;106:2168-2172.</span>
</li>
<li id="cite_note-:6-6"><span class="mw-cite-backlink"><a href="#cite_ref-:6_6-0">↑</a></span> <span class="reference-text">Ceballos EM, Parrish RK, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology 2002;109:2256-2260.</span>
</li>
<li id="cite_note-:7-7"><span class="mw-cite-backlink"><a href="#cite_ref-:7_7-0">↑</a></span> <span class="reference-text">Papadaki TG, Zacharopoulos IP, Pasquale LR, et al. Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol 2007;144:62-69. Brown RD, Cairns JE. Experience with the Molteno long tube implant. Trans Ophthalmol Soc UK 1983;103:297-312.</span>
</li>
<li id="cite_note-:8-8"><span class="mw-cite-backlink"><a href="#cite_ref-:8_8-0">↑</a></span> <span class="reference-text">Mermoud A, Salmon JF, Alexander P, et al. Molteno tube implantation for neovascular glaucoma: long term results and factors influencing out¬come. Ophthalmology 1993;100:897-902.</span>
</li>
<li id="cite_note-:9-9"><span class="mw-cite-backlink"><a href="#cite_ref-:9_9-0">↑</a></span> <span class="reference-text">Hill RA, Nguyen QH, Baerveldt G, et al. Trabeculectomy and Molteno implantation for glaucomas associated with uveitis. Ophthalmology 1993;100:903-908.</span>
</li>
<li id="cite_note-:10-10"><span class="mw-cite-backlink"><a href="#cite_ref-:10_10-0">↑</a></span> <span class="reference-text">Sidoti PA, Dunphy TR, Baerveldt G, et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology 1995;102:1107-1118.</span>
</li>
<li id="cite_note-damata11-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-damata11_11-0">11.0</a></sup> <sup><a href="#cite_ref-damata11_11-1">11.1</a></sup> <sup><a href="#cite_ref-damata11_11-2">11.2</a></sup></span> <span class="reference-text">Da Mata A, Burk SE, Netland PA, et al. Management of uveitic glaucoma with Ahmed glaucoma valve implantation. Opthalmology 1999;106:2168-2172.</span>
</li>
<li id="cite_note-ceballos12-12"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ceballos12_12-0">12.0</a></sup> <sup><a href="#cite_ref-ceballos12_12-1">12.1</a></sup> <sup><a href="#cite_ref-ceballos12_12-2">12.2</a></sup></span> <span class="reference-text">Ceballos EM, Parrish RK, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology 2002;109:2256-2260.</span>
</li>
<li id="cite_note-papadaki13-13"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-papadaki13_13-0">13.0</a></sup> <sup><a href="#cite_ref-papadaki13_13-1">13.1</a></sup> <sup><a href="#cite_ref-papadaki13_13-2">13.2</a></sup></span> <span class="reference-text">Papadaki TG, Zacharopoulos IP, Pasquale LR, et al. Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol 2007;144:62-69.</span>
</li>
<li id="cite_note-billson14-14"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-billson14_14-0">14.0</a></sup> <sup><a href="#cite_ref-billson14_14-1">14.1</a></sup> <sup><a href="#cite_ref-billson14_14-2">14.2</a></sup></span> <span class="reference-text">Billson F, Thomas R, Aylward W. The use of two-stage molten implants in developmental glaucoma. Journal of Pediatric Ophthalmology and Strabismus 1989;26:3-8.</span>
</li>
<li id="cite_note-munoz15-15"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-munoz15_15-0">15.0</a></sup> <sup><a href="#cite_ref-munoz15_15-1">15.1</a></sup> <sup><a href="#cite_ref-munoz15_15-2">15.2</a></sup></span> <span class="reference-text">Munoz M, Tomey KF, Traverso C, et al. Clinical experience with the Molteno implant in advanced infantile glaucoma. J Ped Ophthalmol Strabismus 1991;28:68-72.</span>
</li>
<li id="cite_note-netland16-16"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-netland16_16-0">16.0</a></sup> <sup><a href="#cite_ref-netland16_16-1">16.1</a></sup></span> <span class="reference-text">Netland PA, Walton DS. Glaucoma drainage implants in pediatric patients. Ophthalmic Surg 1993;24:723-729.</span>
</li>
<li id="cite_note-coleman17-17"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-coleman17_17-0">17.0</a></sup> <sup><a href="#cite_ref-coleman17_17-1">17.1</a></sup> <sup><a href="#cite_ref-coleman17_17-2">17.2</a></sup></span> <span class="reference-text">Coleman AL, Smyth RJ, Wilson RM, et al. Initial clinical experience with the Ahmed glaucoma valve implant in pediatric patients. Arch Ophthalmol 1997;115:186-191.</span>
</li>
<li id="cite_note-netland18-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-netland18_18-0">18.0</a></sup> <sup><a href="#cite_ref-netland18_18-1">18.1</a></sup></span> <span class="reference-text">Netland PA, Terada H, Dohlman CH. Glaucoma associated with keratoprosthesis. Ophthalmology 1998;105:751-757.</span>
</li>
<li id="cite_note-:19-19"><span class="mw-cite-backlink"><a href="#cite_ref-:19_19-0">↑</a></span> <span class="reference-text">Ayyala RS, Harman LE, Michelini-Norris B, et al. Comparison of different biomaterials for glaucoma drainage devices. Arch Ophthalmol 1999;117:233-236.</span>
</li>
<li id="cite_note-:20-20"><span class="mw-cite-backlink"><a href="#cite_ref-:20_20-0">↑</a></span> <span class="reference-text">Ayyala RS, Michelini-Norris B, Flores A, et al. Comparison of different biomaterials for glaucoma drainage devices: part 2. Arch Ophthalmol 2000;118;1081-1084.</span>
</li>
<li id="cite_note-mackenzie21-21"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-mackenzie21_21-0">21.0</a></sup> <sup><a href="#cite_ref-mackenzie21_21-1">21.1</a></sup></span> <span class="reference-text">Mackenzie PJ, Schertzer RM, Isbister CM. Comparison of silicone and polypropylene Ahmed glaucoma valves: two-year follow-up. Can J Ophthalmol 2007;42:227-232.</span>
</li>
<li id="cite_note-:22-22"><span class="mw-cite-backlink"><a href="#cite_ref-:22_22-0">↑</a></span> <span class="reference-text">Brasil MVOM, Rockwood EJ, Smith S. Comparison of silicone and polypropylene Ahmed glaucoma valve implants. J Glaucoma 2007;16:36-41.</span>
</li>
<li id="cite_note-:23-23"><span class="mw-cite-backlink"><a href="#cite_ref-:23_23-0">↑</a></span> <span class="reference-text">Ishida K, Netland PA, Costa VP, et al. Comparison of polypropylene and silicone Ahmed glaucoma valves. Ophthalmology 2006;113:1320-1326.</span>
</li>
<li id="cite_note-heuer24-24"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-heuer24_24-0">24.0</a></sup> <sup><a href="#cite_ref-heuer24_24-1">24.1</a></sup> <sup><a href="#cite_ref-heuer24_24-2">24.2</a></sup></span> <span class="reference-text">Heuer DK, Lloyd MA, Abrams DA, et al. Which is better? One or two? A randomized clinical trial of single-plate versus double-plate Molteno implantation for glaucoma in aphakia and pseudophakia. Ophthalmology 1992;99:1512-1519.</span>
</li>
<li id="cite_note-ayyala25-25"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ayyala25_25-0">25.0</a></sup> <sup><a href="#cite_ref-ayyala25_25-1">25.1</a></sup></span> <span class="reference-text">Ayyala RS, Zurakowski D, Monshizadeh R, et al. Comparison of double-plate Molteno and Ahmed glaucoma valve in patients with advanced uncontrolled glaucoma. Ophthalmic Surg and Lasers 2002;33:94-101.</span>
</li>
<li id="cite_note-lloyd26-26"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-lloyd26_26-0">26.0</a></sup> <sup><a href="#cite_ref-lloyd26_26-1">26.1</a></sup> <sup><a href="#cite_ref-lloyd26_26-2">26.2</a></sup></span> <span class="reference-text">Lloyd MA, Baerveldt G, Fellenbaum PS, et al. Intermediate-term results of a randomized clinical trial of the 350 versus the 500 mm<sup>2</sup> Baerveldt implant. Ophthalmology 1994;101:1456-1464.</span>
</li>
<li id="cite_note-:27-27"><span class="mw-cite-backlink"><a href="#cite_ref-:27_27-0">↑</a></span> <span class="reference-text">Britt MT, LaBree LD, Lloyd MA, et al. Randomized clinical trial of the 350-mm<sup>2</sup> versus the 500-mm<sup>2</sup> Baerveldt implant longer term results. Is bigger better? Ophthalmology 1999;106:2312-2318.</span>
</li>
<li id="cite_note-ball28-28"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ball28_28-0">28.0</a></sup> <sup><a href="#cite_ref-ball28_28-1">28.1</a></sup></span> <span class="reference-text">Ball SF, Ellis GS, Herrington RG, et al. Browns superior oblique tendon syndrome after Baerveldt implant. Arch Ophthalmol 1992; 110:1368.</span>
</li>
<li id="cite_note-christman29-29"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-christman29_29-0">29.0</a></sup> <sup><a href="#cite_ref-christman29_29-1">29.1</a></sup></span> <span class="reference-text">Christman LM, Wilson ME: Motility disturbances after Molteno im¬plants. J Ped Ophthalmol Strabismus 1992;29:44-48.</span>
</li>
<li id="cite_note-:30-30"><span class="mw-cite-backlink"><a href="#cite_ref-:30_30-0">↑</a></span> <span class="reference-text">Gross FJ: Six month success of Krupin valve with and without Mitomy-cin-C in the treatment of complicated glaucomas. Invest Ophthalmol Vis Sci 1994 (Suppl);35:l422.</span>
</li>
<li id="cite_note-:31-31"><span class="mw-cite-backlink"><a href="#cite_ref-:31_31-0">↑</a></span> <span class="reference-text">Trible JR, Brown DB. Occlusive ligature and standardized fenestrations of a Baerveldt tube with and without antimetabolites for early postoperative intraocular pressure control. Ophthalmology 1998;105:2243-2250.</span>
</li>
<li id="cite_note-:32-32"><span class="mw-cite-backlink"><a href="#cite_ref-:32_32-0">↑</a></span> <span class="reference-text">Irak I, Moster MR, Fontanarosa J. Intermediate-term results of Baerveldt tube shunt surgery with mitomycin C use. Ophthalmic Surg Laser and Imaging 2004;35:189-196.</span>
</li>
<li id="cite_note-:33-33"><span class="mw-cite-backlink"><a href="#cite_ref-:33_33-0">↑</a></span> <span class="reference-text">Cantor L, Burgoyne J, Sanders S, et al. The effect of mitomycin C on Molteno implant surgery: A 1-year randomized, masked, prospective study. J Glaucoma 1998;7:240-246.</span>
</li>
<li id="cite_note-:34-34"><span class="mw-cite-backlink"><a href="#cite_ref-:34_34-0">↑</a></span> <span class="reference-text">Costa VP, Azuara-Blanco A, Netland PA, et al. Efficacy and safety of adjunctive mitomycin C during Ahmed glaucoma valve implantation: A prospective randomized clinical trial. Ophthalmology 2004;111:1071-1076.</span>
</li>
<li id="cite_note-molteno35-35"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-molteno35_35-0">35.0</a></sup> <sup><a href="#cite_ref-molteno35_35-1">35.1</a></sup></span> <span class="reference-text">Molteno ACB: New implant for drainage in glaucoma: clinical trial. Br J Ophthalmol 1979;53:606-615.</span>
</li>
<li id="cite_note-:36-36"><span class="mw-cite-backlink"><a href="#cite_ref-:36_36-0">↑</a></span> <span class="reference-text">Feldman RM, El-Harazi SM, Villanueva G. Valve membrane adhesion as a cause of Ahmed glaucoma valve failure. J Glaucoma 1996;6:10-12.</span>
</li>
<li id="cite_note-:37-37"><span class="mw-cite-backlink"><a href="#cite_ref-:37_37-0">↑</a></span> <span class="reference-text">Hill RA, Pirouzian A, Liaw LH. Pathophysiology of and prophylaxis against late Ahmed glaucoma valve occlusion. Am J Ophthalmol 2000;129:608-612.</span>
</li>
<li id="cite_note-:38-38"><span class="mw-cite-backlink"><a href="#cite_ref-:38_38-0">↑</a></span> <span class="reference-text">Sarkisian SR, Netland PA. Tube extender for revision of glaucoma drainage implants. J Glaucoma 2007;16:637-639.</span>
</li>
<li id="cite_note-:39-39"><span class="mw-cite-backlink"><a href="#cite_ref-:39_39-0">↑</a></span> <span class="reference-text">Tessler Z, Jluchoded S, Rosenthal G. Nd:YAG laser for Ahmed tube shunt occlusion by the posterior capsule. Ophthlamic Surg Lasers 1997;28:69-70.</span>
</li>
<li id="cite_note-:40-40"><span class="mw-cite-backlink"><a href="#cite_ref-:40_40-0">↑</a></span> <span class="reference-text">Netland PA, Schuman S. Management of glaucoma drainage implant tube kink and obstruction with pars plana clip. Ophthalmic Surg Lasers Imaging 2005;36:167-168.</span>
</li>
<li id="cite_note-:41-41"><span class="mw-cite-backlink"><a href="#cite_ref-:41_41-0">↑</a></span> <span class="reference-text">Tarbak AAA, Shahwan SA, Jadaan IA, et al. Endophthalmitis associated with the Ahmed glaucoma valve implant. Br J Ophthalmol 2005;89:454-458.</span>
</li>
<li id="cite_note-beebe42-42"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-beebe42_42-0">42.0</a></sup> <sup><a href="#cite_ref-beebe42_42-1">42.1</a></sup></span> <span class="reference-text">Beebe WE, Starita RJ, Fellman RL. The use of the Molteno implant and anterior chamber tube shunt to encircling band for the treatment of glaucoma in keratoplasty patients. Ophthalmology 1990;97:1414-22.</span>
</li>
<li id="cite_note-:43-43"><span class="mw-cite-backlink"><a href="#cite_ref-:43_43-0">↑</a></span> <span class="reference-text">Sherwood MB, Smith MF, Driebe WT Jr., et al. Drainage tube implants in the treatment of glaucoma following penetrating keratoplasty. Ophthalmic Surg 1993;24(3):185-189.</span>
</li>
<li id="cite_note-:44-44"><span class="mw-cite-backlink"><a href="#cite_ref-:44_44-0">↑</a></span> <span class="reference-text">McDonell PJ, Robin JB, Schanzlin DJ, et al. Molteno implant for control of glaucoma in eyes after penetrating keratoplasty. Ophthalmology 1988;95(3):364-369. </span>
</li>
<li id="cite_note-:45-45"><span class="mw-cite-backlink"><a href="#cite_ref-:45_45-0">↑</a></span> <span class="reference-text">Lloyd MA, Sedlak T, Heuer DK, et al. Clinical experience with the single-plate Molteno implant in complicated glaucomas. Update of a pilot study. Ophthalmology 1992;99(5):679-687. </span>
</li>
<li id="cite_note-:46-46"><span class="mw-cite-backlink"><a href="#cite_ref-:46_46-0">↑</a></span> <span class="reference-text">Munoz M, Parrish RK. Prospective evaluation of extraocular motility following double-plate Molteno implantation. Arch Ophthalmol1999;117;1155-1160. </span>
</li>
<li id="cite_note-:47-47"><span class="mw-cite-backlink"><a href="#cite_ref-:47_47-0">↑</a></span> <span class="reference-text">Ventura MP, Vianna RN, Souza Filho JP, et al. Acquired Brown’s syndrome secondary to Ahmed valve implant for neovascular glaucoma. Eye 2005;19:230-232.</span>
</li>
<li id="cite_note-:48-48"><span class="mw-cite-backlink"><a href="#cite_ref-:48_48-0">↑</a></span> <span class="reference-text">Ayyala RS, Zurakowski D, Smith JA, et al. A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma. Ophthalmology 1998;105:1968-1976.</span>
</li>
<li id="cite_note-:49-49"><span class="mw-cite-backlink"><a href="#cite_ref-:49_49-0">↑</a></span> <span class="reference-text">Nouri-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of the Ahmed glaucoma valve. Am J Ophthalmol 2003;136:1001-1008.</span>
</li>
<li id="cite_note-:50-50"><span class="mw-cite-backlink"><a href="#cite_ref-:50_50-0">↑</a></span> <span class="reference-text">Smith M, Geffen N, Alasbali T, et al. Digital ocular massage for hypertensive phase after Ahmed valve surgery. J Glaucoma 2010;19:11-14</span>
</li>
<li id="cite_note-:51-51"><span class="mw-cite-backlink"><a href="#cite_ref-:51_51-0">↑</a></span> <span class="reference-text">Freedman J. Clinical Experience with the Molteno dual-chamber single-plate implant. Ophthalmic Surg 1992;23:238-241.</span>
</li>
<li id="cite_note-:52-52"><span class="mw-cite-backlink"><a href="#cite_ref-:52_52-0">↑</a></span> <span class="reference-text">Syed HM, Law SK, Nam SH, et al. Baerveldt-350 implant versus Ahmed valve for refractory glaucoma: a case-controlled comparison. J Glaucoma 2004;13:38-45.</span>
</li>
<li id="cite_note-wang53-53"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-wang53_53-0">53.0</a></sup> <sup><a href="#cite_ref-wang53_53-1">53.1</a></sup></span> <span class="reference-text">Wang JC, See JL, Chew PT. Experience with the use of Baerveldt and Ahmed glaucoma drainage implants in an Asian population. Ophthalmology 2004;111:1383-1388.</span>
</li>
<li id="cite_note-tsai54-54"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-tsai54_54-0">54.0</a></sup> <sup><a href="#cite_ref-tsai54_54-1">54.1</a></sup> <sup><a href="#cite_ref-tsai54_54-2">54.2</a></sup> <sup><a href="#cite_ref-tsai54_54-3">54.3</a></sup></span> <span class="reference-text">Tsai JC, Johnson CC, Kammer JA, et al. The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma II: longer-term outcomes from a single surgeon. Ophthalmology 2006;113:913-917.</span>
</li>
<li id="cite_note-:55-55"><span class="mw-cite-backlink"><a href="#cite_ref-:55_55-0">↑</a></span> <span class="reference-text">Budenz DL,Barton K, Feuer WJ, et al. Treatment outcomes in the Ahmed Baerveldt Comparison (ABC) Study after one yearof follow-up. Paper presented at: The 20th Annual American Glaucoma Society Meeting; March 4, 2010; Naples, FL.</span>
</li>
<li id="cite_note-:56-56"><span class="mw-cite-backlink"><a href="#cite_ref-:56_56-0">↑</a></span> <span class="reference-text">Barton K, Budenz DL, Gedde SJ, et al. Surgical complications in the Ahmed Baerveldt Comparison (ABC) Study during the first year of follow-up. Paper presented at: The 20th Annual American Glaucoma Society Meeting; March 5, 2010; Naples, FL.</span>
</li>
<li id="cite_note-57"><span class="mw-cite-backlink"><a href="#cite_ref-57">↑</a></span> <span class="reference-text">Christakis PG, Zhang D, Barton K, Thai JC, Ahmed IIK, ABC-AVB Study Groups. Five-Year Pooled Data Analysis of the Ahmed Baerveldt Comparison Study and the Ahmed Versus Baerveldt Study. Am J Ophthalmol 2017;176:118-26.</span>
</li>
<li id="cite_note-:57-58"><span class="mw-cite-backlink"><a href="#cite_ref-:57_58-0">↑</a></span> <span class="reference-text">Al-Jazzaf AM, Netland PA, Charles S. Incidence and management of elevated intraocular pressure after silicone oil injection. J Glaucoma 2005;14:40-46.</span>
</li>
<li id="cite_note-:58-59"><span class="mw-cite-backlink"><a href="#cite_ref-:58_59-0">↑</a></span> <span class="reference-text">Coleman AL, Mondino BJ, Wilson MR, et al. Clinical experience with the Ahmed glaucoma valve implant in eyes with prior or current penetrating keratoplasties. Am J Ophthalmol 1997;123:54-</span>
</li>
<li id="cite_note-:59-60"><span class="mw-cite-backlink"><a href="#cite_ref-:59_60-0">↑</a></span> <span class="reference-text">Ayyala RS, Pieroth L, Vinals AF, et al. Comparison of mitomycin C trabeculectomy, glaucoma drainage device implantation, and laser neodymium: YAG cyclophotocoagulation in the management of intractable glaucoma after penetrating keratoplasty. Ophthalmology 1998;105:1550-1556.</span>
</li>
<li id="cite_note-englert60-61"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-englert60_61-0">61.0</a></sup> <sup><a href="#cite_ref-englert60_61-1">61.1</a></sup></span> <span class="reference-text">Englert JA, Freedman SF, Cox TA. The Ahmed valve in refractory pediatric glaucoma. Am J Ophthalmol 1999;127:34-42.</span>
</li>
<li id="cite_note-budenz61-62"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-budenz61_62-0">62.0</a></sup> <sup><a href="#cite_ref-budenz61_62-1">62.1</a></sup></span> <span class="reference-text">Budenz DL, Sakamoto D, Eliezer R, et al. Two-staged Baerveldt glaucoma implant for childhood glaucoma associated with Sturge-Weber syndrome. Ophthalmology 2000;107:2105-2110.</span>
</li>
<li id="cite_note-:62-63"><span class="mw-cite-backlink"><a href="#cite_ref-:62_63-0">↑</a></span> <span class="reference-text">Djodeyre MR, Calvo JP, Gomez JA. Clinical evaluation and risk factors of time to failure of Ahmed glaucoma valve implant in pediatric patients. Ophthalmology 2001;108:614-620.</span>
</li>
<li id="cite_note-:63-64"><span class="mw-cite-backlink"><a href="#cite_ref-:63_64-0">↑</a></span> <span class="reference-text">Wilson MR, Mendis U, Smith SD, et al. Ahmed glaucoma valve implant vs. trabeculectomy in the surgical treatment of glaucoma: A randomized clinical trial. Am J Ophthalmol 2000;130:267-273.</span>
</li>
<li id="cite_note-:64-65"><span class="mw-cite-backlink"><a href="#cite_ref-:64_65-0">↑</a></span> <span class="reference-text">Wilson MR, Mendis U, Paliwal A, et al. Long-term follow-up of primary glaucoma surgery with Ahmed glaucoma valve implant versus trabeculectomy. Am J Ophthalmol 2003;136:464-470.</span>
</li>
<li id="cite_note-:65-66"><span class="mw-cite-backlink"><a href="#cite_ref-:65_66-0">↑</a></span> <span class="reference-text">Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol 2007;143:9-22.</span>
</li>
<li id="cite_note-:66-67"><span class="mw-cite-backlink"><a href="#cite_ref-:66_67-0">↑</a></span> <span class="reference-text">Gedde SJ, Herndon LW, Brandt JD, et al. Surgical complications in the tube versus trabeculectomy study during the first year follow-up. Am J Ophthalmol 2007;143:23-31.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035155
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.001 seconds
CPU time usage: 0.312 seconds
Real time usage: 2.287 seconds
Preprocessor visited node count: 1426/1000000
Post‐expand include size: 6993/2097152 bytes
Template argument size: 1528/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 35163/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  798.831      1 Template:Article
100.00%  798.831      1 -total
 91.27%  729.067      4 Template:Infobox_section
 61.05%  487.720     11 Template:UserLookup
  5.33%   42.540      1 Template:Review_expired
  4.07%   32.549      1 Template:Get_active_contest
  0.12%    0.949      1 Template:Infobox_end
  0.12%    0.942      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Glaucoma_Drainage_Devices&amp;oldid=89560">https://eyewiki.org/w/index.php?title=Glaucoma_Drainage_Devices&amp;oldid=89560</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyw1gvt">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Glaucoma_Drainage_Devices" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Glaucoma_Drainage_Devices" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Glaucoma_Drainage_Devices&amp;oldid=89560" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Glaucoma_Drainage_Devices&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on February 10, 2023, at 10:43.</div>
					<div>This page has been accessed 296,350 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.001},"limitreport":{"cputime":"0.312","walltime":"2.287","ppvisitednodes":{"value":1426,"limit":1000000},"postexpandincludesize":{"value":6993,"limit":2097152},"templateargumentsize":{"value":1528,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":35163,"limit":5000000},"timingprofile":["100.00%  798.831      1 Template:Article","100.00%  798.831      1 -total"," 91.27%  729.067      4 Template:Infobox_section"," 61.05%  487.720     11 Template:UserLookup","  5.33%   42.540      1 Template:Review_expired","  4.07%   32.549      1 Template:Get_active_contest","  0.12%    0.949      1 Template:Infobox_end","  0.12%    0.942      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035155","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":3199});});</script></body>
</html>